Form 4: Hologic Executive Reports Ownership Changes Post-Merger

Hologic Inc. Chief Financial Officer Karleen Marie Oberton reports on changes in beneficial ownership following the company's merger.

Summary

• Karleen Marie Oberton, Chief Financial Officer of Hologic Inc., has filed a Form 4 detailing changes in her beneficial ownership of company securities.
• The filing indicates that as of April 7, 2026, Oberton no longer beneficially owns any shares of Hologic common stock directly or indirectly due to a merger.
• Prior to the merger, Oberton held various non-qualified stock options and performance stock units.
• These options and units were converted into rights to receive merger consideration, which included cash and contingent value rights (CVRs).
• Specifically, each share of Hologic common stock was converted into $76.00 in cash and one CVR for up to $3.00 in cash.
• Options with an exercise price below the cash consideration were converted into cash and CVRs, while those with higher exercise prices were converted into CVRs or cancelled for no consideration.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine disclosure of insider transactions following a merger and does not provide new operational or financial performance data.

Positives

• The merger consideration provides a cash payout of $76.00 per share, plus a potential additional $3.00 per share via CVRs, indicating a significant value realization for shareholders and option holders.
• Performance stock units (PSUs) were deemed achieved at the greater of target or actual performance levels, maximizing potential payouts for these awards.
• The reporting person, as CFO, is actively managing her equity holdings in accordance with the merger terms.

Negatives

• Options with exercise prices at or above $79.00 ($76.00 cash consideration + $3.00 CVR) were cancelled for no consideration, representing a loss for those specific option holders.
• The contingent value rights (CVRs) introduce uncertainty, as the additional $3.00 per share is not guaranteed and depends on future events or conditions.

Risks

• The value of the contingent value rights (CVRs) is uncertain and dependent on specific conditions being met, posing a risk of not receiving the full potential payout.
• Options with exercise prices higher than the cash consideration plus the maximum CVR value were cancelled without compensation, representing a complete loss for those specific option holders.

Future Outlook

The filing primarily details past transactions related to a merger. The future outlook for Hologic as a private entity is not detailed in this Form 4. The contingent value rights (CVRs) represent a potential future payout, but the conditions for payment are not specified in this document.

Management Comments

• The filing is a statement of changes in beneficial ownership and does not contain direct management comments or quotes.
• The attorney-in-fact, Mark W. Irving, signed on behalf of Ms. Oberton.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting insider transactions, especially following significant corporate events like mergers. The conversion of equity awards into cash and contingent value rights is a common structure in 'take-private' transactions, aiming to provide value to existing equity holders while allowing the acquirer to take the company private.

Stakeholder Impact

• Shareholders: Received cash and CVRs, representing the realization of their investment value, with potential for additional payout from CVRs.
• Option Holders: Those with options below the cash consideration received cash and CVRs; those with options above a certain threshold received only CVRs or nothing.
• Employees: As the company is now privately held, employees' equity holdings (RSUs, PSUs, options) have been converted as per the merger terms.

Next Steps

• The reporting person has completed the reporting of changes in beneficial ownership related to the merger.
• The contingent value rights (CVRs) may lead to future payments if certain conditions are met, which would be reported in subsequent filings if applicable.

Key Dates

Keywords

Form 4, Hologic Inc, HOLX, Karleen Marie Oberton, Chief Financial Officer, Merger, Beneficial Ownership, Stock Options, Performance Stock Units, Contingent Value Rights, SEC Filing